Ma BT, Sang LX, Chang B. Gastric microbiota transplantation as a potential treatment for immune checkpoint inhibitor-associated gastritis. World J Gastroenterol 2024; 30(24): 3123-3125 [PMID: 38983955 DOI: 10.3748/wjg.v30.i24.3123]
Corresponding Author of This Article
Bing Chang, MD, PhD, Chief Physician, Professor, Department of Gastroenterology, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning Province, China. cb000216@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 28, 2024; 30(24): 3123-3125 Published online Jun 28, 2024. doi: 10.3748/wjg.v30.i24.3123
Gastric microbiota transplantation as a potential treatment for immune checkpoint inhibitor-associated gastritis
Bo-Tong Ma, Li-Xuan Sang, Bing Chang
Bo-Tong Ma, Bing Chang, Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Li-Xuan Sang, Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110022, Liaoning Province, China
Author contributions: Ma BT wrote the original draft; Sang LX and Chang B revised the manuscript; and all authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: There are no conflicts of interest to report.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bing Chang, MD, PhD, Chief Physician, Professor, Department of Gastroenterology, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning Province, China. cb000216@163.com
Received: April 27, 2024 Revised: May 27, 2024 Accepted: June 13, 2024 Published online: June 28, 2024 Processing time: 58 Days and 18.1 Hours
Abstract
Immune-related adverse events (irAEs) are complications of the use of immune checkpoint inhibitors (ICIs). ICI-associated gastritis is one of the main irAEs. The gastric microbiota is often related to the occurrence and development of many gastric diseases. Gastric microbiota adjustment may be used to treat gastric disorders in the future. Faecal microbiota transplantation can alter the gut microbiota of patients and has been used for treating ICI-associated colitis. Therefore, we propose gastric microbiota transplantation as a supplementary treatment for patients with ICI-associated gastritis who do not respond well to conventional therapy.
Core Tip: The gastric microbiota is often related to the occurrence and development of many gastric diseases. Faecal microbiota transplantation has been used for treating immune checkpoint inhibitor (ICI)-associated colitis. Therefore, gastric microbiota transplantation is a promising treatment for ICI-associated gastritis.
